In addition, the identification of a gene signature associated with BC cell sensitivity to CD32-CR T cells and predicting the favorable clinical course of BC in a retrospective study of 1,400 patients with advanced disease opens new unsuspected investigation pathways in the field of innate cell and tumor biology. This evidence concerns the gene FCGR2A and breast cancer.